AUTHOR=Huang Bao , Wang Jiasheng , Zhang Xuyang , Xie Ziang , Wu Hao , Liu Junhui , Jie Zhiwei , Zhao Xiangde , Qin An , Fan Shunwu , Chen Jian , Zhao Fengdong TITLE=Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss via Suppressing Osteoclastogenesis in Mice JOURNAL=Frontiers in Pharmacology VOLUME=10 YEAR=2019 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00900 DOI=10.3389/fphar.2019.00900 ISSN=1663-9812 ABSTRACT=
Activation of osteoclast formation and function is crucial for the development of osteolytic diseases such as osteoporosis. RANKL (receptor activator of nuclear factor-κB ligand) activates NF-κB (nuclear factor κB), MAPK (mitogen-activated protein kinase), and NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1) signaling pathways to induce osteoclastogenesis. In this study, we demonstrated that SB239063, a p38-specific inhibitor, suppressed osteoclastogenesis and bone resorption